Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancer

BACKGROUND: Extensive-disease small-cell lung cancer (ED-SCLC) is characterized by rapid progression and relapse, despite high initial response rates to chemotherapy. The primary objective of this trial was to demonstrate the non-inferiority of amrubicin and cisplatin (AP) combination therapy compar...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:BMC Cancer
Auteurs principaux: Sun, Yan, Cheng, Ying, Hao, Xuezhi, Wang, Jie, Hu, Chengping, Han, Baohui, Liu, Xiaoqing, Zhang, Li, Wan, Huiping, Xia, Zhongjun, Liu, Yunpeng, Li, Wei, Hou, Mei, Zhang, Helong, Xiu, Qingyu, Zhu, Yunzhong, Feng, Jifeng, Qin, Shukui, Luo, Xiaoyan
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2016
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4826513/
https://ncbi.nlm.nih.gov/pubmed/27061082
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-016-2301-6
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires